Hematologic Malignancies

Diagnostic and Treatment Services

Learn More About

Multiple Myeloma Treatments at the University of Maryland Greenebaum Cancer Center
Understanding Leukemia and Lymphoma: an Interview with Dr. Maria Baer

Patients with hematologic malignancies often have a complex array of medical issues. Our Program for Hematologic Malignancies brings together a team of specialists to provide patients with individualized treatment plans without duplicating services. Patients are evaluated by:

Medical oncologists/hematologists
Specialized nurses, nurse practitioners, and research nurses
Radiation oncologists
Pathologists
Nutritionists
Social workers

The Program for Hematologic Malignancies offers a comprehensive range of diagnostic and treatment services designed to provide patients with the most effective care possible. Services include:

On-site specialized diagnostic and support services, including hematopathology, molecular diagnosis, immunophenotyping, special cell component therapy and pheresis, and infectious disease specialists
Integrated programs with the Blood and Marrow Transplant Program
Second opinions
New therapies

We also treat benign hematology – bleeding disorders, red cell disorders, platelet abnormalities and white cell disorders.

A major goal of Hematologic Malignancies Program is to develop new curative approaches for leukemias, lymphomas and myelomas. For example:

We offer a number of NCI-funded Phase I and II innovative clinical trials of new drugs and novel drug combinations for patients with newly diagnosed or relapsed and/or refractory leukemias and myelodysplasia.
We use novel immunotherapy approaches to treat Chronic Myelogenous Leukemia (CML), lymphoma and multiple myeloma.
We offer new molecularly-targeted drugs for multiple myeloma.

If you would like to make an appointment, or if you are a physician with a patient who would benefit from the expertise and treatment we offer, please call us at 1-800-888-8823

This page was last updated on: August 10, 2007.